A number of firms have modified their ratings and price targets on shares of Ultragenyx Pharmaceutical (NASDAQ: RARE) recently:

  • 8/16/2017 – Ultragenyx Pharmaceutical is now covered by analysts at Evercore ISI. They set a $63.00 price target on the stock.
  • 8/8/2017 – Ultragenyx Pharmaceutical had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock, up previously from $72.00.
  • 8/1/2017 – Ultragenyx Pharmaceutical was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/28/2017 – Ultragenyx Pharmaceutical was given a new $98.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/27/2017 – Ultragenyx Pharmaceutical is now covered by analysts at Sanford C. Bernstein. They set a “market perform” rating and a $72.00 price target on the stock.
  • 7/25/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/18/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
  • 7/14/2017 – Ultragenyx Pharmaceutical had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $68.00 price target on the stock.
  • 7/11/2017 – Ultragenyx Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
  • 6/30/2017 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $111.00 price target on the stock.
  • 6/29/2017 – Ultragenyx Pharmaceutical had its “outperform” rating reaffirmed by analysts at Cowen and Company. They wrote, “We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community.””
  • 6/22/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 6/20/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of Ultragenyx Pharmaceutical Inc. (RARE) traded up 0.59% during mid-day trading on Wednesday, reaching $61.34. 146,085 shares of the company were exchanged. Ultragenyx Pharmaceutical Inc. has a 12 month low of $51.67 and a 12 month high of $91.35. The stock’s market capitalization is $2.60 billion. The firm has a 50-day moving average price of $64.68 and a 200 day moving average price of $67.01.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the consensus estimate of ($1.73) by $0.01. During the same quarter last year, the firm posted ($1.46) EPS. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($7.24) EPS for the current fiscal year.

In other news, VP Theodore Alan Huizenga sold 480 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $57.46, for a total transaction of $27,580.80. Following the completion of the sale, the vice president now owns 9,366 shares in the company, valued at approximately $538,170.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 9.20% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.